Ingrid Glimelius

Professor vid Institutionen för immunologi, genetik och patologi, Cancerprecisionsmedicin; Forskargrupp Ingrid Glimelius

Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Akademiska sjukhuset, ingång 100/101
751 85 Uppsala

Kort presentation

Senior Consultant and professor Department of Immunology Genetics and Pathology, Uppsala University.

I conduct both clinical trials and large register-based investigations with a specific focus on Lymphoma.

I am also affiliated to the Clinical Epidemiology Unit, Karolinska Institutet.

I study etiology, prognosis and late-effects (childbearing) in patients burdened by lymphatic malignancies.

My research projects also cover many translational projects at the Pathology Department.

Akademiska meriter: Leg läk, Professor

Nyckelord: hodgkin lymphoma survivorship ovarian cancer testicular cancer childbirth after cancer mantle cell lymphoma cancer epidemiology

MD, Uppsala University 2001

PHD, Uppsala University 2009, Hodgkin lymphoma – an interplay between tumour cell and microenvironment

MD, specialist Internal Medicine 2011

MD, specialist Oncology 2013

Associate Professor in Oncology 2016

Good Clinical Practice, Investigator Site Personnel ICH-GCP 2017

Senior Consultant Oncology 2019

Professor 2022

Hodgkin lymphoma

Hodgkin lymphoma affects young adults and is today a curable disease with intensive chemotherapy. In our group we do population-based studies focusing on both survival and survivorship questions for those young patients. Our most recent research will also focus on a specific subtype, nodular lymphocyte predominant Hodgkin lymphoma, and on risk and prognostic factors for classical Hodgkin lymphoma.

Example of our research previously published in Journal of Clinical Oncology, show that the childbearing potential in survivors after Hodgkin lymphoma is good in the abscence of relapse for female patients. Recent investigations now also focus on male patients. We have been investigating this together with researcher at Karolinska Institutet Caroline Weibull. We show that in the absence of relapse, contemporarily treated women have an improved childbearing potential with calendar time and women treated today give birth to the same degree as matched comparators.

In a related publication in Journal of Clinical Oncology from 2016 we have earlier shown the safety of having children for female survivors, were there was no increased risk of relapse after a pregnancy

Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators.

Weibull CE, Johansson ALV, Eloranta S, Smedby KE, Björkholm M, Lambert PC, Dickman PW, Glimelius I. J Clin Oncol. 2018 Jul 25:JCO2018783514. doi: 10.1200/JCO.2018.78.3514. [Epub ahead of print] PMID: 30044694

Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma.

Weibull CE, Eloranta S, Smedby K, Björkholm M, Kristinsson SY, Johansson AL, Dickman PW, Glimelius I. J Clin Oncol. 2016 Feb 1;34(4):337-44. doi: 10.1200/JCO.2015.63.3446. Epub 2015 Dec 14. PMID: 26668344

Mantle Cell Lymphoma

Mantle cell lymphoma is today one of the lymphomas with poor prognosis. I am national principal investigator in the ongoing ALTAMIRA-trial and in the recently closed ENRICH-trial (KFUE Akademiska Sjukhuset):

ALTAMIRA is a phase II trial investigating the second generation Bruton tyrosine kinase inhibitor Acalabrutinib together with Rituximab in elderly mantle cell lymphoma patients. The research question is if a minimal residual disease (MRD) driven treatment strategy can be used and if treatment time can be guided by MRD measurments.

ENRICH is a randomized phase III trial in elderly patients with randomization between Rituximab-Ibrutinib AND Rituximab-chemotherapy (Bendamustine or CHOP) with the aim to test if a chemotherapy free concept can improve survival.

In addition I am local PI of the VALERIA trial in Uppsala testing Lenalidomide-Venetoclax and Rituximab for relapsed/refractory mantle cell lymphoma patients.

We also participate in trials with bispecific antibodies (GENMAB001, with sc. epcoritamab) and with antibody drug conjugates (ROR-1 inhibitors and MMAE) for relapsed refractory mantle cell lymphoma. With this broad effort we can provide patients with a range of new treatment concepts.

In addition I am currently investigating the impact of associated diseases on the prognosis of Mantle Cell Lymphoma. PHD students interested in the field are welcome to contact me.

Pregnancy and the risk of cancer

In two recent articles published in International Journal of Cancer and a comprehensive review published in Journal of Internal Medicine the associations between pregnancies and later cancer risk in the mother is examined. In the first article we show that a full length pregnancy protects against epithelial ovarian cancer to a higher extent than a pregnancy resulting in preterm delivery. In the next article, we show a decreased risk of breast cancer for females experiencing high blood pressure prior to and during pregnancy. In the review we both illustrate and discuss different aspects of pregnancy and a later risk of several solid malignancies.

Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.

Sköld C, Bjørge T, Ekbom A, Engeland A, Gissler M, Grotmol T, Madanat-Harjuoja L, Gulbech Ording A, Stephansson O, Trabert B, Tretli S, Troisi R, Toft Sørensen H, Glimelius I.

Int J Cancer. 2018 May 8. doi: 10.1002/ijc.31581. [Epub ahead of print] PMID:29737528

Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.

Troisi R, Gulbech Ording A, Grotmol T, Glimelius I, Engeland A, Gissler M, Trabert B, Ekbom A, Madanat-Harjuoja L, Toft Sørensen H, Tretli S, Bjørge T.

Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600. [Epub ahead of print] PMID: 29752724

The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence.

Troisi R, Bjørge T, Gissler M, Grotmol T, Kitahara CM, Myrtveit Saether SM, Ording AG, Sköld C, Sørensen HT, Trabert B, Glimelius I.J Intern Med. 2018 May;283(5):430-445. doi: 10.1111/joim.12747. Epub 2018 Mar 25. PMID:29476569

Kontakta katalogansvarig vid den aktuella organisationen (institution eller motsv.) för att rätta ev. felaktigheter.

Ingrid Glimelius
Senast uppdaterad: 2021-03-09